Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

C D Forbes

Showing results (81-90 of 313) with videos related to

Pageof 32
Sort By:
Nature|June 19, 1975
Possible pathway for formation of fibrin degradation products during ancrod therapyC McKillop, W Edgar, C D Forbes, et al.
Scottish Medical Journal|July 31, 1998
Heart and arterial disease risk factors measured in an office workforce: changes from 1993 to 1996. The Scottish Heart and Arterial Risk Prevention Group (SHARP)S R McEwan, C Hau, F Daly, et al.
Urological Research|November 10, 1976
The incidence of deep vein thrombosis in prostatectomised patients following the administration of the fibrinolytic inhibitor, aminocaproic acid (EACA)J Sinclair, C D Forbes, C R Prentice, et al.
Haemostasis|January 1, 1983
Contribution of the haematocrit to the bleeding timeM Small, G D Lowe, E Cameron, et al.
Clinical Science|April 1, 1973
Potentiation of platelet aggregation and adhesion by heparin both in vivo and in vitroC Thompson, C D Forbes, E Martin, et al.
Health Bulletin|March 1, 1985
Adult polycystic kidney disease: a study of medical and social problemsP Wilkie, I Markova, C D Forbes, et al.
Thrombosis Research|September 1, 1975
In vivo production of soluble complexes containing fibrinogen-fibrin related antigen during ancrod therapyC McKillop, W Edgar, C D Forbes, et al.
Arthritis and Rheumatism|September 1, 1988
Mechanisms of joint damage in an experimental model of hemophilic arthritisR Madhok, D Bennett, R D Sturrock, et al.
Scottish Medical Journal|May 1, 1975
Soluble fibrin complex production and proteolysis during ancrod therapyC McKillop, W Edgar, C R Prentice, et al.
British Journal of Haematology|June 1, 1974
Proceedings: Detection of carriers of haemophilia using linear discriminant analysisC R Prentice, C D Forbes, S Smith, et al.
Pageof 32

Showing results (81-90 of 313) with videos related to

Sort By:
Pageof 32
Nature|June 19, 1975
Possible pathway for formation of fibrin degradation products during ancrod therapyC McKillop, W Edgar, C D Forbes, et al.
Scottish Medical Journal|July 31, 1998
Heart and arterial disease risk factors measured in an office workforce: changes from 1993 to 1996. The Scottish Heart and Arterial Risk Prevention Group (SHARP)S R McEwan, C Hau, F Daly, et al.
Urological Research|November 10, 1976
The incidence of deep vein thrombosis in prostatectomised patients following the administration of the fibrinolytic inhibitor, aminocaproic acid (EACA)J Sinclair, C D Forbes, C R Prentice, et al.
Haemostasis|January 1, 1983
Contribution of the haematocrit to the bleeding timeM Small, G D Lowe, E Cameron, et al.
Clinical Science|April 1, 1973
Potentiation of platelet aggregation and adhesion by heparin both in vivo and in vitroC Thompson, C D Forbes, E Martin, et al.
Health Bulletin|March 1, 1985
Adult polycystic kidney disease: a study of medical and social problemsP Wilkie, I Markova, C D Forbes, et al.
Thrombosis Research|September 1, 1975
In vivo production of soluble complexes containing fibrinogen-fibrin related antigen during ancrod therapyC McKillop, W Edgar, C D Forbes, et al.
Arthritis and Rheumatism|September 1, 1988
Mechanisms of joint damage in an experimental model of hemophilic arthritisR Madhok, D Bennett, R D Sturrock, et al.
Scottish Medical Journal|May 1, 1975
Soluble fibrin complex production and proteolysis during ancrod therapyC McKillop, W Edgar, C R Prentice, et al.
British Journal of Haematology|June 1, 1974
Proceedings: Detection of carriers of haemophilia using linear discriminant analysisC R Prentice, C D Forbes, S Smith, et al.
Pageof 32